Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-05
2011-04-05
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S194000
Reexamination Certificate
active
07919507
ABSTRACT:
Disclosed are N-aroyl cyclic amine derivatives having the formula:wherein the substituent variables are as defined herein, and their use as pharmaceuticals.
REFERENCES:
patent: 5547978 (1996-08-01), Christensen et al.
patent: 6326379 (2001-12-01), Macor et al.
patent: 6677354 (2004-01-01), Branch et al.
patent: 6706720 (2004-03-01), Atwal et al.
patent: 2004/0180887 (2004-09-01), Branch et al.
patent: 2004/0192673 (2004-09-01), Gaillard et al.
patent: 2004/0215014 (2004-10-01), Chan et al.
patent: 2006/0040937 (2006-02-01), Branch et al.
patent: WO 00/08015 (2000-02-01), None
patent: WO 00/12077 (2000-03-01), None
patent: WO 00/71508 (2000-11-01), None
patent: WO 01/40231 (2001-06-01), None
patent: WO 01/96302 (2001-12-01), None
patent: WO 02/44172 (2002-06-01), None
Brisbare-Roch et al.Nature Medicine, 13(2): 150-155 (2007).
Hagan et al.Proc. Natl. Acad. Sci. USA., 96: 10911-10916 (1999).
Piper et al.Eur. J. Neurosci., 12: 726-730 (2000).
Patani et al.Chem. Rev., 96: 3147-3176 (1996).
Boutrel et al.PNAS, 102(52): 19168-19173 (2005).
Borgland et al.Neuron, 49: 589-601 (2006).
Harris et al.Nature, 437: 556-559 (2005).
King.Med. Chem.: Principle&Practice, 206-209 (1994).
Patini et al.Chem. Rev., 96: 3147, 3148, 3130 (1996).
Rubini et al.Tetrahedron, 42(21): 6039-6045 (1986).
Langmead et al.Br. J. Pharmacol., 141: 340-346 (2004).
Porter et al.Bioorg.&Med. Chem. Lett., 11: 1907-1910 (2001).
Duxon et al.Psychopharmacology, 153: 203-209 (2001).
White et al.Peptides, 26: 2331-2338 (2005).
Ishii et al.Behav. Brain Res., 160: 11-24 (2005).
Ishii et al.Behav. Brain Res., 157: 331-341 (2005).
Ishii et al.Physiol.&Behav., 81: 129-140 (2004).
Smith et al.Neurosci. Lett., 341: 256-258 (2003).
Haynes et al.Regulatory Peptides, 104: 153-159 (2002).
Bingham et al.Pain, 92: 81-90 (2001).
Rodgers et al.Eur. J. Neurosci., 13: 1444-1452 (2001).
Smart et al.Br. J. Pharmacol., 132: 1179-1182 (2001).
Jones et al.Psychopharmacology, 153: 210-218 (2001).
Haynes et al.Regulatory Peptides, 96: 45-51 (2000).
Rodgers et al.Neuropeptides, 36(5): 303-325 (2002).
Mori et al.Chem. Pharm. Bull., 32(10): 3840-3847 (1984).
Defoin et al.Helv. Chim. Acta, 75(1): 109-123 (1992).
Smart et al.European J. Pharmacol., 440: 199-212 (2002).
Lang et al.J. Med. Chem., 47: 1153-1160 (2004).
Kilduff et al.Trends Neurosci., 23: 359-365 (2000).
Taheri et al.Annu. Rev. Neurosci., 25: 283-313 (2002).
Cai et al.Expert Opin. Ther. Patents, 16(5): 631-646 (2006).
Branch Clive Leslie
Coulton Steven
Johns Amanda
Johnson Christopher Norbert
Porter Roderick Alan
Ling Lorraine
Morris Patricia L
Sieburth Kathryn L.
SmithKline Beecham Limited
LandOfFree
N-aroyl cyclic amines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-aroyl cyclic amines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-aroyl cyclic amines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2632392